Medical News
Addiction
Allergies
Alternative Medicine
Asthma
Cancer
Cardiology
Chiropractic
Dental
Dermatology
Diabetes
Emergency
Family Medicine
General
Geriatrics
Hospitals
Infectious Diseases
Internal Medicine
Managed Care / HMO
Medical Products
Mental Health
Neurology
Nursing
Nutrition
OB / GYN
Pediatrics
Pharmaceuticals
Physical Therapy
Plastic Surgery
Psychology
Radiology / Imaging
Research
Sports Medicine
Surgery
Vision

North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential

www.painreductiontherapy.com/infrex1.php
www.painreductiontherapy.com/infrex1.php

Portable device can be used in home, rather than hospital, and can be worn for treatment anytime, anywhere, including work.

(PRWEB) January 13, 2009 -- MedFaxx (http://www.medfaxxinc.com) has announced the release of the first FDA approved, insurance reimbursable unit that combines the most used form of electrotherapy in the world clinically for chronic pain, interferential with TENS (transcutaneous electrical nerve stimulation) which is the most used form of electrotherapy for chronic pain outside the clinic. The Infrex Plus (http://www.painreductiontherapy.com/infrex1.php) unit means those individuals suffering from agonizing pain can now self-treat without the use of narcotics, at home or work, on an as needed basis.

Historically interferential (8,000+ pulses per second) was only used for patients in a clinical setting. Each session cost the patient or insurance company for each treatment. The benefit of interferential is immediate pain relief (http://www.painreductiontherapy.com/infrex1.php) that provides 'carryover' pain relief that can last for hours, days, and sometimes weeks.

With the release of the new combination unit a patient can treat at home, work, or wherever pain starts, whenever it starts. The patient is no longer dependent upon scheduling an appointment, being denied treatment by the insurance company, or having to take time off from work to get relief. The new unit is small enough, yet powerful enough, for the patient to wear/carry and use during breaks or on the job to self treat to.

The overall savings from missing work will be in the mega millions of dollars for the employer and employee.

Bob Johnson of MedFaxx Inc. said: "The Infrex Plus unit means those individuals suffering from agonizing pain can now self-treat without the use of narcotics, at home or work, on an as needed basis."

The breakthrough is the result of new-patented engineering technology that allows the use of portable, rechargeable batteries that can sustain enough energy for the patient to receive up to two treatments using only the battery system. In most settings, it is preferred the unit be plugged into a wall outlet with the AC adaptor. The engineering efficiency of using either batteries or AC adaptor means more patients can stay on the job, be active with their families, and not worry about the onset of crippling pain.

Interferential is not new. It's been around since 1951 but has been regarded as "experimental" by Medicare even though it is the most effective form of electrotherapy for pain in the world. Due to the classification, Medicare patients had to be treated with interferential only in clinical settings. Medicare would deny the purchase of an interferential unit, even though the patient's pain was resolved. The new Infrex Plus unit solved this problem by combining a Medicare approved unit, TENS, with the interferential mode into one unit so a patient can choose which treatment is best and have the unit paid for by the insurance company, including Medicare.

The overall savings to the U.S. health care system will be significant. Patients can obtain relief without having to go to clinics. This dramatically reduces the cost of chronic pain management to patients, insurance companies, and Medicare.

The company, MedFaxx, offers a free trial of the Infrex Plus unit, for the patient to determine its efficacy before any purchase is made. During the trial, the company consults with the insurance company to make sure coverage is provided and if not MedFaxx will work with any patient to insure the patient is treated.

For over 30+ years the company has operated on the premise that no deserving patients will be denied access to its equipment due to lack of funds. As the only unit approved by the FDA., a prescription is required from a licensed medical doctor before the unit can be sent for the free trial. The company works with the patient and doctor to facilitate this process. For a free trial visit here: http://www.painreductiontherapy.com/infrex1.php

More information can be obtained by visiting the website, http://www.medfaxxinc.com or by calling Bob Johnson at 800-937-3993 - 9 a.m. - 5 p.m. EST.

###

Simillar Articles

Lakota Canada Announces Release of Triple Strength Back Pain -- Clinically Proven Natural Back...
Lakota announces the release of a 100% natural back pain product, proven as effective as a prescription drug. Lakota Triple Strength Back Pain is the first chemical free back pain reliever to hit...
Drug-Free Pain Relief: Chicago Pain Management Physicians Pioneer Hybrid Approach to Relieving...
Chicago pain management specialists Eugene, Lipov, MD, and Jay Joshi, MD, have combined two nerve stimulation techniques to relieve the unremitting pain of failed back surgery syndrome -- without...
Kest Laboratories, Inc. Announces Release of Superior OTC MDRelief Pain Relieving Cream
A leading laboratory announces the release of a new pain relieving cream. This pain relieving cream uses natural ingredients in a topical form to ease aches, pains and bruises. Key ingredients...
Forbes names Spine-health.com Best of The Web in Health
Spine-health.com, the leading health information website for consumers with chronic pain and back pain, was named to Forbes.com's Best of The Web Directory.
New Pain Therapeutics Summit 2007 Announced
Arrowhead Conferences' Pain Therapeutics Summit 2007 brings together leaders from the pharmaceutical community to discuss new avenues of research in the field of pain therapeutics and the...
Home Terms of Use Privacy Policy Contact Us